The following are Delgoffe lab and associated publications - feel free to contact for reprints.


original manuscripts

Dayana B. Rivadeneira, Kristin DePeaux, Yiyang Wang, Aditi Kulkarni, Tracy Tabib, Ashley V. Menk, Padmavathi Sampath, Robert Lafyatis, Robert L. Ferris, Saumendra N. Sarkar, Stephen H. Thorne, Greg M. Delgoffe. “Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance” Immunity. 2019 Aug 27.

Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, Zhai S, Kirkwood JM, Delgoffe GM. “Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.” JCI Insight. 2019 Feb 5.

Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM. “4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses.” Journal of Experimental Medicine. 2018 March 6.

Menk AV*, Scharping NE*, Moreci RS, Zeng X, Guy C, Salvatore S, Bae H,
Xie J, Young HA, Wendell SG, Delgoffe GM. "Early TCR Signaling Induces Rapid
Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions." Cell Reports. 2018 Feb 6.

Scharping NE*, Menk AV*, Whetstone RD, Zeng X, and Delgoffe GM. "Efficacy of PD-1 blockade immunotherapy is potentiated by metformin-induced reduction of tumor hypoxia." Cancer Immunol Res. 2016 Dec 10.

Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, and Delgoffe GM. “The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction.” Immunity 2016 Aug 2.

review articles

Zavras PD, Wang Y, Gandhi A, Lontos K, Delgoffe GM. “Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date.” Onco Targets Ther. 2019 June 11.

Rivadeneira DB and Delgoffe GM. "Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy" Clinical Cancer Research 2018 Jan 31.

Scharping NE and Delgoffe GM. "Tumor microenvironment metabolism: a new checkpoint for anti-tumor immunity." Vaccines (Basel) 2016 Dec 6.

Delgoffe GM. "Filling the tank: keeping anti-tumor T cells metabolically fit for the long haul." Cancer Immunol Res. 2016 Dec 4.

Delgoffe GM. "VHL Brings Warburg into the Memory Spotlight." Immunity. 2016 Nov 15.

Delgoffe GM and Powell JD. “Feeding an army: the metabolism of T cells in activation, anergy, and exhaustion.” Mol Immunol. 2015 Dec.

collaborative manuscripts

Chang Liu, Maria Chikina, Rahul Deshpande, Ashley V. Menk, Ting Wang, Tracy Tabib, Erin A. Brunazzi, Kate M. Vignali, Ming Sun, Donna B. Stolz, Robert A. Lafyatis, Wei Chen, Greg M. Delgoffe, Creg J. Workman, Stacy G. Wendell, and Dario A.A. Vignali. “Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-g” Immunity. 2019 Aug 20.

Alicia R. Watson, Helong Dai, Yawen Zheng, Ryosuke Nakano, Anastasios D. Giannou, Ashley V. Menk, Donna B. Stolz, Greg M. Delgoffe, and Angus W. Thomson. “mTORC2 Deficiency Alters the Metabolic Profile of Conventional Dendritic Cells” Front. Immunol., 2019 July 2.

Shao L, Hou W, Scharping NE, Vendetti FP, Srivastava R, Roy CN, Menk AV, Wang Y, Chauvin JM, Karukonda P, Thorne SH, Hornung V, Zarour HM, Bakkenist CJ, Delgoffe GM, Sarkar SN. “IRF1 inhibits antitumor immunity through the upregulation of PD-L1 in the tumor cell” Cancer Immunol Res. 2019 June 25.

Piccirillo AR, Hyzny EJ, Beppu LY, Menk AV, Wallace CT, Hawse WF, Buechel HM, Wong BH, Foo JC, Cazenave-Gassiot A, Wenk MR, Delgoffe GM, Watkins SC, Silver DL, D'Cruz LM. “The Lysophosphatidylcholine Transporter MFSD2A Is Essential for CD8+ Memory T Cell Maintenance and Secondary Response to Infection.” J Immunol. 2019 May 24.

Santos PM, Menk AV, Shi J, Tsung A, Delgoffe GM, Butterfield LH.  “Tumor-derived α-fetoprotein suppresses fatty acid metabolism and oxidative phosphorylation in dendritic cells.” Cancer Immunol Res. 2019 Apr 15.

Majumder S, Amatya N, Revu S, Jawale CV, Wu D, Rittenhouse N, Menk A, Kupul S, Du F, Raphael I, Bhattacharjee A, Siebenlist U, Hand TW, Delgoffe GM, Poholek AC, Gaffen SL, Biswas PS, McGeachy MJ. “IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival.” Nat Immunol. 2019 Apr 8.

Previte DM, Martins CP, O'Connor EC, Marre ML, Coudriet GM, Beck NW, Menk AV, Wright RH, Tse HM, Delgoffe GM, Piganelli JD. “Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells.” Cell Rep. 2019 Apr 2.

Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ. “Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted.” J Clin Invest. 2018 Nov 1.

Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ. “ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.” J Clin Invest. 2018 Aug 31.

Revu S, Wu J, Henkel M, Rittenhouse N, Menk A, Delgoffe GM, Poholek AC, McGeachy MJ. “IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation.” Cell Rep. 2018 Mar 6.

Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi, EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ, and Vignali DAA. “Interferon-gamma drive Treg fragility to promote anti-tumor immunity. Cell. 2017 Jun 1.

Downs-Canner S, Berkley S, Delgoffe GM, Edwards R, Curiel T, Odunsi K, Bartlett D, and Obermajer N. “Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumor-associated Treg cells.” Nat Commun. 2017 Mar 14.

Phong B, Avery L, Menk AVDelgoffe GM, Kane LP. "Cutting Edge: Murine Mast Cells Rapidly Modulate Metabolic Pathways Essential for Distinct Effector Functions." J Immunol. 2017 Jan 15.

Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA, Delgoffe GM, and Wherry EJ. “Bioenergetic insufficiencies due to metabolic alterations regulated by PD-1 are an early driver of CD8+ T cell exhaustion.” Immunity 2016 Aug 2.

Pollizzi KN, Sun IH, Patel CH, Lo YC, Oh MH, Waickman AT, Tam AJ, Blosser RL, Wen J, Delgoffe GM, Powell JD. “Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation.” Nat Immunol. 2016 Apr 11.

Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA. “Interleukin-35 limits anti-tumor immunity.” Immunity. 2016 Feb 16.

greg's previous major papers

Delgoffe GM*, Woo SR*, Turnis ME, Guy CS, Overacre AE, Gravano DM, Bettini ML, Finkelstein DF, Bonnevier J, Vogel P, Workman CJ and Vignali DA. “Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis.” Nature. 2013 Sep 12.

Collison LW*, Delgoffe GM*, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DA. “The composition and signaling of the IL-35 receptor are unconventional.” Nat Immunol. 2012 Feb 5.

Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, and Powell JD. “The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.” Nat Immunol. 2011 Feb 27.

Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthew KL, Xiao B, Worley PF, Kozma SC, Powell JD. “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.” Immunity. 2009 Jun 19.

Zheng Y*, Delgoffe GM*, Meyer CF*, Chan W, Powell JD. "Anergic T cells are metabolically anergic." J Immunol. 2009 Oct 19.